What is the recommended starting dose of escitalopram (Lexapro) in adults, and how does it differ for patients ≥ 65 years or with hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Starting Dose of Lexapro (Escitalopram)

The standard starting dose of Lexapro is 10 mg once daily for most adults, but elderly patients (≥65 years) and those with hepatic impairment should start and remain at 10 mg daily as their maximum dose. 1

Standard Adult Dosing

For adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD):

  • Initial dose: 10 mg once daily
  • Recommended maintenance: 10 mg once daily
  • Maximum dose: 20 mg once daily
  • Can be taken morning or evening, with or without food 1

The FDA label explicitly states that no additional benefits were observed at 20 mg once daily compared to 10 mg 1, making the standard 10 mg dose appropriate for most patients.

Special Populations Requiring Dose Modification

Elderly Patients (≥65 Years)

Elderly patients should receive 10 mg daily as both their starting AND maximum dose 1. This recommendation is based on:

  • Escitalopram half-life increases by approximately 50% in patients ≥65 years compared to younger adults 1
  • Pharmacokinetic studies show prolonged drug exposure in elderly patients 2
  • Greater risk of clinically significant hyponatremia in this population 1
  • Clinical data from a 2023 study of 19,742 patients showed that 20% of patients >65 years reached potentially pro-arrhythmic concentrations with just 10 mg escitalopram 3

Important caveat: While guidelines from 2015 suggest starting elderly patients at approximately 50% of the adult dose 4, the FDA label is more conservative and specific, recommending 10 mg as the maximum dose for elderly patients 1.

Hepatic Impairment

Patients with hepatic impairment should receive 10 mg daily as their maximum dose 1. This is because:

  • Increased escitalopram exposure occurs in hepatic impairment 1
  • Studies show AUC increases of 51-72% in patients with hepatic disease 5
  • CYP2C19 activity is a better predictor of clearance than Child-Pugh classification 5

Renal Impairment

No dose adjustment is necessary for mild or moderate renal impairment 1. However, escitalopram has not been evaluated in patients with creatinine clearance <20 mL/minute 1.

Pediatric Dosing

For adolescents ≥12 years with MDD or children ≥7 years with GAD:

  • Initial and recommended dose: 10 mg once daily
  • Maximum: 20 mg once daily 1

Clinical Considerations

Monitoring in high-risk patients: All patients >65 years, those using additional QTc-prolonging drugs, or those with predisposition for arrhythmias should undergo therapeutic drug monitoring to keep serum concentrations below 100 nM 3. This is particularly critical given that 20% of elderly patients on 10 mg may reach potentially cardiotoxic levels 3.

Duration of treatment: Continue for 4-12 months after first episode of major depression; patients with recurrent depression may benefit from prolonged treatment 4.

Discontinuation: When stopping Lexapro, reduce dose gradually whenever possible 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.